Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
More News related to GHDX
- Genomic Health (GHDX) Tops Q3 EPS by 7c
- Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
- Genomic Health Announces Analyst Day Webcast Presentation to be Held on November 12, 2009
More News related to Upgrades
- CPI Aerostructures (CVU) Posts Q3 EPS of $0.15, Misses Estimates; Revs Light
- FirstCity Financial (FCFC) Posts Q3 EPS of 19c, Shy of Estimates; Revs Beat
- Beazer Homes (BZH) Posts Q4 Profit On Early Debt Payment
- RHI Entertainment (RHIE) Posts Q3 Loss of $1.24, Misses Views; Revs Light
- Heartland Payment Systems (HPY) Posts Q3 Loss of $0.99, Wider than Estimated
Thomas Weisel upgrades Genomic Health (Nasdaq: GHDX) from Marketweight to Overweight. Price target $23.
To see more analyst ratings on GHDX Click Here.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer.
Related Categories
UpgradesStocks Mentioned
+0.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
